CellaVision AB (CEVI)

Currency in SEK
173.00
+2.80(+1.65%)
Closed·
CEVI Scorecard
Full Analysis
Trading at a high P/E ratio relative to near-term earnings growth
CEVI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
169.20173.60
52 wk Range
147.80302.00
Key Statistics
Prev. Close
170.2
Open
170
Day's Range
169.2-173.6
52 wk Range
147.8-302
Volume
22.12K
Average Volume (3m)
15.53K
1-Year Change
-30.81%
Book Value / Share
34.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CEVI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
228.00
Upside
+31.79%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

CellaVision AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

CellaVision AB Company Profile

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company’s CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.

Employees
229
Market
Sweden

CellaVision AB Earnings Call Summary for Q2/2025

  • CellaVision reported Q2 2025 revenue of 191M SEK, with 7.8% organic growth, slightly below forecast but driving 2.77% stock increase
  • Gross margin remained strong at 68%, with EBITDA of 60M SEK and 31% margin; R&D spend increased to 22% of sales
  • APAC region saw 27% organic growth, highlighting successful expansion efforts in Asia
  • Company expects margin improvements and continues R&D investment, with CE Mark for bone marrow module anticipated by 2026
  • InvestingPro analysis indicates excellent financial health with a score of 3.04/5, suggesting strong operational fundamentals
Last Updated: 18/07/2025, 11:06
Read Full Transcript

Compare CEVI to Peers and Sector

Metrics to compare
CEVI
Peers
Sector
Relationship
P/E Ratio
26.9x−10.6x−0.5x
PEG Ratio
6.42−0.110.00
Price/Book
4.9x2.9x2.6x
Price / LTM Sales
5.4x817.8x3.3x
Upside (Analyst Target)
36.8%0.0%43.5%
Fair Value Upside
Unlock5.7%6.3%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 228.00
(+31.79% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.34%
Dividend Yield
1.47%
Industry Median 1.56%
Annualised payout
2.50
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jul 18, 2025
EPS / Forecast
1.60 / 1.65
Revenue / Forecast
191.15M / 191.50M
EPS Revisions
Last 90 days

CEVI Income Statement

People Also Watch

597.10
ASML
-0.88%
236.90
TCFP
+0.17%
173.00
AIRP
+0.44%
456.50
LVMH
-1.25%
51.90
TTEF
+0.62%

FAQ

What Stock Exchange Does CellaVision AB Trade On?

CellaVision AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for CellaVision AB?

The stock symbol for CellaVision AB is "CEVI."

What Is the CellaVision AB Market Cap?

As of today, CellaVision AB market cap is 4.13B.

What Is CellaVision AB's Earnings Per Share (TTM)?

The CellaVision AB EPS (TTM) is 6.34.

When Is the Next CellaVision AB Earnings Date?

CellaVision AB will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is CEVI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has CellaVision AB Stock Split?

CellaVision AB has split 1 times.

How Many Employees Does CellaVision AB Have?

CellaVision AB has 229 employees.

What is the current trading status of CellaVision AB (CEVI)?

As of 05 Aug 2025, CellaVision AB (CEVI) is trading at a price of 173.00, with a previous close of 170.20. The stock has fluctuated within a day range of 169.20 to 173.60, while its 52-week range spans from 147.80 to 302.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.